Navigation Links
Early Switch to an Aromatase Inhibitor Increases Survival

For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates//, according to a new study. The study reveals that the clear survival benefit was also achieved without an increased risk of death from other causes – a significant risk associated with tamoxifen.

Hormone modulating therapies have made a significant impact on the survival rates of women with estrogen-sensitive breast cancer over the last two decades. The drugs are used as adjuvant to primary surgical treatment for a period of five years.

Tamoxifen was the first estrogen modulator shown to increase survival and reduce the risk of breast cancer recurrence. However, tamoxifen is associated with increased risk of death from other causes, such as strokes and endometrial cancer. Despite this risk, tamoxifen and another drug in this class, raloxifene, remain an extensively used and popular treatment.

Aromatase inhibitors, such as aminoglutethimide and anastrozole, work in a different way to lower estrogen levels. Recent evidence shows aromatase inhibitors used alone or in follow-up after two years of tamoxifen therapy demonstrates clear and, in some cases, improved reduction of recurrence risk. However, there is conflicting evidence about mortality benefits.

Led by Professor Francesco Boccardo, M.D. of the National Cancer Research Institute and the University of Genoa in Italy, researchers pooled data from two studies (828 women) comparing five year treatment with tamoxifen alone (415 women) or tamoxifen for two to three years followed by an aromatase inhibitor for the remaining treatment period (413 women).

Dr. Boccardo and his colleagues found that compared to treatment with tamoxifen alone, all cause mortality risk and breast cancer-related mortality risk both fell significantly for women switching to an aromatase inhibitor. In addition, there was no increased risk of de ath from other causes in women who were prescribed the aromatase inhibitor.

"This pooled analysis provides solid evidence that switching to an aromatase inhibitor following a few years of tamoxifen treatment, implies a mortality benefit over continued tamoxifen and that the benefit on breast cancer-related mortality is mainly due to the effect of switching," conclude the authors.

Source-Eurekalert
'"/>




Related medicine news :

1. Early detection of prostate cancer
2. Early detection of heart attack
3. Early puberty linked to nutrition
4. Early Clue to Down Syndrome
5. Early delivery can prevent cancer
6. Early puberty more resistance
7. Early menopause- The cause
8. Early menopause- The cause
9. Early Warning System For Breast Cancer
10. Early therapy aids eyesight
11. Early detection of colorectal cancer may be hindered by coloured toilet disinfectants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... KS (PRWEB) , ... January 24, 2017 , ... ... Premensa, a leading natural supplement for relieving premenstrual syndrome, or PMS . ... at some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Mysteries Revealed On Speaking In Tongues”: ... is available to all Christians. “Mysteries Revealed On Speaking In Tongues” is the creation ... a Christian-based talk show located in Michigan. , “We need to partner with ...
(Date:1/24/2017)... ... January 23, 2017 , ... The Pharmacy and Medically Underserved ... bipartisan original co-sponsorship of nearly one-quarter of the U.S. House of Representatives. The ... Chain Drug Stores (NACDS) strongly backs the legislation. , “NACDS thanks for their ...
(Date:1/24/2017)... ... January 23, 2017 , ... The ... Buzzies users who entered metrics into the product’s app. The data replicates ... data showed that within just 30 seconds of using Buzzies, people experienced a ...
(Date:1/23/2017)... ... 23, 2017 , ... PKF O’Connor Davies , LLP, the nation’s 26th ... at the Firm, will participate in the 40th Annual "Empire State Building Run Up" ... up 1,576 steps, a vertical distance equal to about a fifth of a mile, ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Jan. 23, 2017 LifeVac, the revolutionary device ... airway and prevented choking deaths, welcomes Steve Way ... the LifeVac team as Official Spokesperson. ... LifeVac team," said Arthur Lih , Founder and ... LifeVac and his mission to raise awareness about the ...
(Date:1/23/2017)... 23, 2017 Research and Markets has announced the ... - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... trends to identify the investment opportunities Market forecasts till ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... January 23, 2017 Stock-Callers.com today presents ... (NASDAQ: CPRX ), Sophiris Bio Inc. (NASDAQ: ... ), and Agile Therapeutics Inc. (NASDAQ: AGRX ). ... somewhat lower in late trade on Friday, January 20 th ... 0.3%, while shares of health care companies in the S&P ...
Breaking Medicine Technology: